Ultragreen.ai Set to Benefit from Greater Indocyanine Green Demand

Dow Jones

Jun 29

0235 GMT - UltraGreen.ai stands to benefit from greater indocyanine green demand across both established and emerging surgical procedures, Phillip Securities' Hashim Osman says in commentary. ICG usage is expected to increase by double digits across the majority of procedures using fluorescence-guided surgery by 2028, the analyst says. The main driver is ICG becoming a standard of care, with major surgical societies incorporating ICG into their clinical guidelines, the analyst adds. The Singapore-based company supplies imaging agents such as indocyanine green for fluorescence-guided surgery. The brokerage initiates coverage of the stock with a buy rating and a target price of US$1.92. Shares are 0.8% higher at US$1.24. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

June 28, 2026 22:35 ET (02:35 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2647347828"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2647347828\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2647347828?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647347828","market":"other","top_or_hot":-1,"title":"Ultragreen.ai Set to Benefit from Greater Indocyanine Green Demand","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0235 GMT - <a href=\"https://laohu8.com/S/ULG.SI\">UltraGreen.ai</a> stands to benefit from greater indocyanine green demand across both established and emerging surgical procedures, Phillip Securities' Hashim Osman says in commentary. ICG usage is expected to increase by double digits across the majority of procedures using fluorescence-guided surgery by 2028, the analyst says. The main driver is ICG becoming a standard of care, with major surgical societies incorporating ICG into their clinical guidelines, the analyst adds. The Singapore-based company supplies imaging agents such as indocyanine green for fluorescence-guided surgery. The brokerage initiates coverage of the stock with a buy rating and a target price of US$1.92. Shares are 0.8% higher at US$1.24. (ronnie.harui@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 28, 2026 22:35 ET (02:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ultragreen.ai Set to Benefit from Greater Indocyanine Green Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltragreen.ai Set to Benefit from Greater Indocyanine Green Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-29 10:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0235 GMT - <a href=\"https://laohu8.com/S/ULG.SI\">UltraGreen.ai</a> stands to benefit from greater indocyanine green demand across both established and emerging surgical procedures, Phillip Securities' Hashim Osman says in commentary. ICG usage is expected to increase by double digits across the majority of procedures using fluorescence-guided surgery by 2028, the analyst says. The main driver is ICG becoming a standard of care, with major surgical societies incorporating ICG into their clinical guidelines, the analyst adds. The Singapore-based company supplies imaging agents such as indocyanine green for fluorescence-guided surgery. The brokerage initiates coverage of the stock with a buy rating and a target price of US$1.92. Shares are 0.8% higher at US$1.24. (ronnie.harui@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 28, 2026 22:35 ET (02:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999006266.SGD","symbol_name":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647347828","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647347828","pubTimestamp":1782700500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0235 GMT - UltraGreen.ai stands to benefit from greater indocyanine green demand across both established and emerging surgical procedures, Phillip Securities' Hashim Osman says in commentary. ICG usage is expected to increase by double digits across the majority of procedures using fluorescence-guided surgery by 2028, the analyst says. The main driver is ICG becoming a standard of care, with major surgical societies incorporating ICG into their clinical guidelines, the analyst adds. The Singapore-based company supplies imaging agents such as indocyanine green for fluorescence-guided surgery. The brokerage initiates coverage of the stock with a buy rating and a target price of US$1.92. Shares are 0.8% higher at US$1.24.  Dow Jones NewswiresJune 28, 2026 22:35 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999006266.SGD":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC","LU0620787316.HKD":"HSBC GIF ASIA EX JAPAN EQUITY SMALLER COMPANIES \"AD\" (HKD) INC","LU0082770016.SGD":"HSBC GIF ASIA EX JAPAN EQUITY SMALLER COMPANIES \"AD\" (SGD) INC","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","LU0082770016.USD":"HSBC GIF ASIA EX JAPAN SMALLER CO. \"AD\" INC","ULG.SI":"优创康智有限公司","LU0164939612.USD":"HSBC GIF ASIA EX JAPAN SMALLER CO. \"AC\" ACC","BK6103":"医疗保健用品"},"translate_title":"Ultragreen.ai将受益于更大的吲哚菁绿需求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ULG.SI":0.9},"content_text":"0235 GMT - UltraGreen.ai stands to benefit from greater indocyanine green demand across both established and emerging surgical procedures, Phillip Securities' Hashim Osman says in commentary. ICG usage is expected to increase by double digits across the majority of procedures using fluorescence-guided surgery by 2028, the analyst says. The main driver is ICG becoming a standard of care, with major surgical societies incorporating ICG into their clinical guidelines, the analyst adds. The Singapore-based company supplies imaging agents such as indocyanine green for fluorescence-guided surgery. The brokerage initiates coverage of the stock with a buy rating and a target price of US$1.92. Shares are 0.8% higher at US$1.24. (ronnie.harui@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 28, 2026 22:35 ET (02:35 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}